Nexentis Technologies Inc. (NASDAQ: NXTS) Advances Drug Discovery with MitoCareX Bio Milestone

May 18, 2026

Expert Analysis Nexentis Technologies Inc. (NASDAQ: NXTS) has demonstrated a significant advancement in its pharmaceutical research capabilities through its subsidiary, MitoCareX Bio Ltd. The development of an optimized hit molecule represents a critical step forward in the company’s drug discovery efforts, potentially accelerating the path toward pre-clinical studies. This progress not only enhances Nexentis’ research profile but may also open avenues for future therapeutic applications. The milestone achieved by MitoCareX…

Read More >>